Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Randy, does a reverse split help/benefit a potential partner or buyer before a partnership or buyout agreement is struck?
I agree with your assessment, things really are coming together. I just hope Rudy is right in predicting basically a quick shot into dollarland after a positive 6 month stop result so that they won't have to do a R/S. Because otherwise, we're going to have to keep loading up "a lot of shares". I can deal with 10:1 split, but not a 20:1 :( :( :(
Thanks efood! ;) gl
Everyone, Please disregard my last two post, and please accept my apologies. I realize I have overlooked some certain points in my readings that now leave me suspicious.
Chart anytime/day you think he may have shorted this stock in the last 90 days in comparison to his positive posts on those given days and I think you'll find that you are mistaking in your "short" claim. jmo
Well, 1234's conclusion certainly warrants a debate. Rudy, I would love to hear from you. And of course anyone else can jump in.
lol...that was so funny. :) :) :)
New website looks pretty good.
Randy,
Hope you've been enjoying the holiday weekend.
Well, wow, where to start? ...I've only been investing for about two years.
I'm only invested in two companies. Two small companies.
In short, at the beginning of my investment venture, I quickly learned to be cautious of certain ways CEO's do business, toxic financing, diluting, insider buying/selling, and unusually high outstanding share counts.
One of the companies I'm in, PharmaCyte Biotech, has me very excited of it's potential, but I remain "cautiously optimistic".
This particular company has a CEO (Kenneth Waggoner), that at one time in his career, headed a company that eventually became a flop.
However, in following his performance through investigative information found on the internet, from his past to present, I seem to be comfortable with him.
With that said, this company has an incredibly interesting drug/device technology (Cell-in-a-Box®) for helping patients with pancreatic cancer and diabetes.
To be successful with this drug/device and bring it to market, the CEO has put together an amazing international consortium of world renowned scientist and physicians, some who have helped in the development of big pharma(s) existing billion dollar drugs.
Over time, having been successful with studies and trials, and recently having a successful pre-IND meeting with the FDA, the company is about to submit an IND to the FDA for a "pivotal" trial.
Some low points:
Nearly 1 billion OS count
No insider buying
PPS remains low (manipulation???)
Dilution (caused by compensation, compensating company execs, staff, and consortium)
Some high points:
No toxic financing, ever
Amazing progress with drug/device delivery platform
IND filing: http://ir.pharmacytebiotech.com/press-releases/detail/133/pharmacyte-biotech-moves-closer-to-filing-ind-with-naming
Pre-IND meeting with the FDA included: https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html
Possible partnership in place (contingency???)
Janssen (Johnson&Johnson owned) attends multiple presentations (btw, Janssen recently dropped Capricor, and Janssen's Aduro fails trial)
Janssen's growing interest in drug/device delivery platform (Janssen has over 30 chemotherapy drugs and NEEDS a successful delivery platform)
NDA's were signed with big pharma: http://pharmacyte.com/pharmacyte-seeks-to-solve-pancreas-puzzle-with-cell-in-a-box/
PR regarding Johnson & Johnson: http://ir.pharmacytebiotech.com/press-releases/detail/82/johnson-johnson-and-big-pharma-could-find-a-diabetes
PharmaCyte then hired a former J & J exec: http://ir.pharmacytebiotech.com/press-releases/detail/94/pharmacyte-biotech-appoints-former-johnson-johnson
PharmaCyte CEO's recent meetings in Canada (Janssen presence/location).
Bavarian Nordic's recent expansion deal with Janssen: https://finance.yahoo.com/news/bavarian-expands-j-j-deal-084519162.html
Bavarian Nordic is the forerunner to Austrianova (PharmaCyte's owns 14.5% equity interest): http://ir.pharmacytebiotech.com/press-releases/detail/29/pharmacyte-biotechs-cancer-treatment-tumor
J & J has the largest presence in Canada of all pharmaceutical companies: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html
Recently, PharmaCyte appointed Dr. Abecassis to their Board of Directors and Dr. Sher as their Chief Medical Officer:
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-michael-m-abecassis-to-board-of-directors/
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-linda-s-sher-as-chief-medical-officer/
My questions are:
With the possibility of having a partner who obviously has the resources needed for trials, should I be worried about a R/S with the OS shares being at 1billion?
PharmaCyte's executives have been compensated with MILLIONS of shares, so should I be worried that there hasn't been any "insider buying"? (personal cash purchases)
Thank you in advance
Some low points:
Nearly 1 billion OS count
No insider buying
PPS remains low (manipulation???)
Dilution (caused by compensation, compensating company execs, staff, and consortium)
Some high points:
No toxic financing, ever
Amazing progress with drug/device delivery platform
IND filing: http://ir.pharmacytebiotech.com/press-releases/detail/133/pharmacyte-biotech-moves-closer-to-filing-ind-with-naming
Pre-IND meeting with the FDA included: https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html
Possible partnership in place (contingency???)
Janssen (Johnson&Johnson owned) attends multiple presentations (btw, Janssen recently dropped Capricor, and Janssen's Aduro fails trial)
Janssen's growing interest in drug/device delivery platform (Janssen has over 30 chemotherapy drugs and NEEDS a successful delivery platform)
NDA's were signed with big pharma: http://pharmacyte.com/pharmacyte-seeks-to-solve-pancreas-puzzle-with-cell-in-a-box/
PR regarding Johnson & Johnson: http://ir.pharmacytebiotech.com/press-releases/detail/82/johnson-johnson-and-big-pharma-could-find-a-diabetes
PharmaCyte then hired a former J & J exec: http://ir.pharmacytebiotech.com/press-releases/detail/94/pharmacyte-biotech-appoints-former-johnson-johnson
PharmaCyte CEO's recent meetings in Canada (Janssen presence/location).
Bavarian Nordic's recent expansion deal with Janssen: https://finance.yahoo.com/news/bavarian-expands-j-j-deal-084519162.html
Bavarian Nordic is the forerunner to Austrianova (PharmaCyte's owns 14.5% equity interest): http://ir.pharmacytebiotech.com/press-releases/detail/29/pharmacyte-biotechs-cancer-treatment-tumor
J & J has the largest presence in Canada of all pharmaceutical companies: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html
Recently, PharmaCyte appointed Dr. Abecassis to their Board of Directors and Dr. Sher as their Chief Medical Officer:
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-michael-m-abecassis-to-board-of-directors/
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-linda-s-sher-as-chief-medical-officer/
Randy, sorry my new board doesn't seem to work. Can I please ask you a general question or two about due diligence? tia
Currently, I don't have private messaging.
Can you meet me in the Lounge? I'm at DD 101
Randy, was your alias ever RandyKsd? tia, Pink
They will, just wait. You'll see it. :) :) :)
Yes, a delivery system that Janssen, for example, can use for some of its many chemotherapy drugs. :) :) :)
Before any buyout I say let John build value in Supreme...maximize it and then later let the buyer pay handsomely for the spoils. :) :) :)
I'm confident we have a customer much bigger than Aurora. :) :) :)
Can't wait to see the entire list of LP's we're servicing.
Yeah, I don't think there's any doubt we're selling to Aurora ...and 2018 will bring nice profits to all!!!
Have a great holiday weekend!!!! ;) ;) ;)
What makes you say that MADD?
And there you have it.
Thanks Rudy and 1234! ;) ;) ;)
I'm sure Rudy will get back to you on that soon enough. I'd be interested in knowing the possibility myself. ;)
Not very good at speculating...sorry. :)
car-T recently approved.
Probably the best thing Juno will ever develop.
CiaB next! :) ;) :)
I looked last night for about an hour myself trying to find any kind of connection between him and PMCB and found nothing.. I was hoping to find a good solid coonection. It would certainly be exciting.
Totally agree!!!!!! ;)
Great!, thank you.
Brian, do you have a particular reason for posting their announcement?
Normal summer slump activity ...stay tuned! :) :) :)
lol I know right? :) :) :)
Capricor Therapeutics and Aduro Biotech recently fails Janssen in both stem cell and pancreas cancer therapy trials.
Janssen now shows interest and attends multiple presentations for PharmaCyte's Cell-in-a-Box therapies; targeted therapies for cancer and diabetes.
NDA's were signed with big pharma: http://pharmacyte.com/pharmacyte-seeks-to-solve-pancreas.../
Thank you Rudy. Brian, thanks, see your FB.
BioInvestor, Brian, and Rudy, could you guys please share your speculations on Sanjay's departure. tia
(ho hum) Again, as you have been told many times before, please do your DD.
Nevermind...I know now.
Who was, or is, Ken Kerr?
You didn't accidentally hide the INTRO did you?
I did not see that particular Facebook page, so I thought it was an honest mistake referring to the 125 year anniversary of Johnson & Johnson, that's all. :)
Ok, thank you 1234. :)